SecBot SecBot
SECBOTREPLAY Home › Report › ARWR

ARWR · Arrowhead Pharmaceuticals appointed Dr

ARROWHEAD PHARMACEUTICALS, INC. · 8-K filed Jun 16, 2026 at 16:02 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 16, 2026 at 16:02 ET

Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manager, to its board of directors effective June 12, 2026. The appointment is routine with standard non-employee director compensation and a sign-on RSU grant of $887,000 vesting over three years.

  • Dr. Matt Cohen appointed as director effective June 12, 2026
  • Cohen brings 25+ years of healthcare investing experience, currently Managing Director at Vida Ventures
  • Sign-on RSU grant valued at $887,000 vesting over three years
  • Standard non-employee director compensation; no family relationships or arrangements

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access